Floatz logo

VITPSO

Cutaneous T Cell Lymphoma

Columbia UniversitySmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

61 Active assets in the Cutaneous T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

VITPSO is also rated in:

mycosis fungoidesDormant
BB
Indicative ·
67 / 100
View asset →
Metastatic Pancreatic AdenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →
Metastatic Pancreatic CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →